Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

PURPOSE: This study investigated the efficacy and tolerability of cabozantinib plus nivolumab (CaboNivo) in patients with metastatic urothelial carcinoma (mUC) that progressed on checkpoint inhibition (CPI). PATIENTS AND METHODS: A phase I expansion cohort of patients with mUC who received prior CPI...

Descripción completa

Detalles Bibliográficos
Autores principales: Girardi, Daniel M., Niglio, Scot A., Mortazavi, Amir, Nadal, Rosa, Lara, Primo, Pal, Sumanta K., Saraiya, Biren, Cordes, Lisa, Ley, Lisa, Ortiz, Olena Sierra, Cadena, Jacqueline, Diaz, Carlos, Bagheri, Hadi, Redd, Bernadette, Steinberg, Seth M., Costello, Rene, Chan, Keith S., Lee, Min-Jung, Lee, Sunmin, Yu, Yunkai, Gurram, Sandeep, Chalfin, Heather J., Valera, Vladimir, Figg, William D., Merino, Maria, Toubaji, Antoun, Streicher, Howard, Wright, John J., Sharon, Elad, Parnes, Howard L., Ning, Yang-Min, Bottaro, Donald P., Cao, Liang, Trepel, Jane B., Apolo, Andrea B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365339/
https://www.ncbi.nlm.nih.gov/pubmed/35031545
http://dx.doi.org/10.1158/1078-0432.CCR-21-3726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365339/
https://www.ncbi.nlm.nih.gov/pubmed/35031545
http://dx.doi.org/10.1158/1078-0432.CCR-21-3726

Ejemplares similares